AstraZeneca share price nosedives as key drug trial disappoints

Tsveta van Son
  • July 27th, 10:44
  • Last Updated: October 21st, 14:54

Shares in AstraZeneca (LON:AZN) have taken a huge plunge this morning, as the initial results of a highly-awaited oncology trial disappointed investors. The blue-chip pharmco further posted a drop in revenue as generic competition to some of its top-selling drugs continued to pressure the company’s performance in the first half of the year.

As of 10:17 BST, AstraZeneca’s share price had lost 16.53 percent to 4,267.50p, weighing on the benchmark FTSE 100 index which is currently 0.05 percent lower at 7,448.78 points. The pharmco’s shares have lost more than eight percent of their value over the past year, and are down by some three percent in the year-to-date.

AstraZeneca announced the outcome of the MYSTIC trial this morning, saying that the combination of Imfinzi and tremelimumab did not meet the primary endpoint of improving progression-free survival compared to chemotherapy in patients with a specific type of lung cancer. The company further noted that although not formally tested, Imfinzi monotherapy would not have met a pre-specified threshold of progression-free survival.

“While the results from the MYSTIC trial for progression free survival in first-line Stage IV non-small cell lung cancer compared with standard of care are disappointing, the trial was designed to assess overall survival and we look forward to evaluating the remaining primary endpoints of overall survival for both mono- and combination therapy,” AstraZeneca’s chief medical officer Sean Bohen commented in the statement.

Ahead of today’s announcements, Mick Cooper, analyst at Trinity Delta, had told The Telegraph that AstraZeneca had “become a one trial company” due to its reliance on the MYSTIC readout.

The blue-chip drugmaker separately updated investors on its interim performance this morning, posting an eight-percent drop in second-quarter revenue to $5 billion, noting that the residual effects of patent losses had impacted product sales. The pharmco’s core earnings per share meanwhile climbed six percent to $0.87.

“Our performance in the first half was in line with expectations as we experience the loss of exclusivity of Crestor and Seroquel XR in the US,” AstraZeneca’s chief executive Pascal Soriot commented in the statement, adding that he was ‘excited about our pipeline-driven transformation’.

The results as well as the outcome of the MYSTIC trial follow recent media reports that Soriot might be headed for generics drugmaker Teva. He, however, recently urged staff to remain focused and ignore rumours. 

As of 10:51 BST, Thursday, 27 July, AstraZeneca plc share price is 4,286.50p.

About the author

Tsveta van Son
Tsveta van Son is part of Invezz’s journalist team. She has a BA degree in European Studies and a MA degree in Nordic Studies from Sofia University and has also attended the University of Iceland. While she covers a variety of investment news, she is particularly interested in developments in the field of renewable energy.

Leave a Reply

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.